We found almost all patients who had severe COVID-19, either hospitalized or who had died, were in the untreated group." Of the 704, 426 (61%) received outpatient treatment, which included nirmatrelvir-ritonavir (n = 307), monoclonal antibodies (n = 105), molnupiravir (n = 5), remdesivir (n = 3), and combination treatment (n = 6). "There are still patients at risk of severe COVID-19, and some of them are in this group of rheumatic patients. Sparks noted that vaccination against COVID-19 confers protection against developing severe COVID-19 in patients with rheumatic disease as it does in the general population, but patients with rheumatic diseases remain at increased risk for severe presentation. COVID rebound was not infrequent: A total of 25 (8%) of 318 patients who received oral outpatient treatment had documented COVID-19 rebound.
For the first time, researchers have used electrical stimulation of the cervical spinal cord to immediately restore arm and hand movement in two patients with chronic moderate-to-severe upper limb paresis. Stroke can disrupt communication between the brain and the spinal cord, leading to motor deficits in the arm and hand. Spinal cord stimulation has shown promise in promoting long-lasting recovery of leg motor function in patients with spinal cord injury; but until now, it's been largely unexplored for upper-limb recovery. In both patients, continuous stimulation of the targeted neural circuits led to significant and immediate improvement in arm and hand strength and dexterity. This enabled the patients to perform movements that they couldn't perform without spinal cord stimulation.1 month ago Medscape
In November 2021, high-priority vulnerable groups became eligible to receive a booster dose, including older adults and healthcare professionals. In a territory-wide retrospective cohort study, the researchers analyzed routine clinical records from public health facilities in Hong Kong. The researchers included 120,724 patients who received the BNT162b2 mRNA vaccine from Fosun-BioNTech (equivalent to Pfizer-BioNTech outside of China), including 87,289 who received a booster dose and 127,318 patients who received Sinovac's CoronaVac shot. For both vaccines, a booster dose was associated with a more than 90% decrease in mortality rate amid the Omicron wave, the authors write. What remains to be addressed is how long after a booster dose does an individual remain protected, and how does this change between populations?1 month ago Medscape
The first part of the book addresses how the pandemic has affected young adults. It associates these effects with the social, political, and economic contexts in which young adults live. Raphael Mendonça Guimarães, PhD, is a public health specialist and researcher at the Sérgio Arouca National School for Public Health, which is affiliated with the Fiocruz. According to Guimarães, the pandemic's "rejuvenation" occurred because distinct demographic dynamics marked Brazil's first 2½ years of the COVID-19 pandemic. At the same time, more young patients were hospitalized for extended periods, leading to a shortage of hospital beds.3 months ago Medscape